Page 130 - 《中国药房》2024年17期

[15] AZZAM A A H，LAMBERT D G. Preclinical discovery sics[J]. Drugs，2023，83（9）：771-793.
and development of oliceridine （Olinvyk ） for the treat‐ [27] DING H P，TRAPELLA C，KIGUCHI N，et al. Functional
®
ment of post-operative pain[J]. Expert Opin Drug Discov， profile of systemic and intrathecal cebranopadol in nonhu‐
2022，17（3）：215-223. man Primates[J]. Anesthesiology，2021，135（3）：482-493.
[16] DAKSLA N，WANG A，JIN Z S，et al. Oliceridine for the [28] HE C B，WANG X L，ZHANG J，et al. MCRT，a multi‐
management of moderate to severe acute postoperative functional ligand of opioid and neuropeptide FF receptors，
pain：a narrative review[J]. Drug Des Devel Ther，2023， attenuates neuropathic pain in spared nerve injury model
17：875-886. [J]. Basic Clin Pharmacol Toxicol，2021，128（6）：731-740.
[17] MANGLIK A，LIN H，ARYAL D K，et al. Structure-based [29] ZHANG M N，XU B，LI N，et al. Development of multi‐
discovery of opioid analgesics with reduced side effects functional and orally active cyclic peptide agonists of
[J]. Nature，2016，537（7619）：185-190. opioid/neuropeptide FF receptors that produce potent，
[18] DING H P，KIGUCHI N，PERREY D A，et al. Antinoci‐ long-lasting，and peripherally restricted antinociception
ceptive，reinforcing，and pruritic effects of the G-protein with diminished side effects[J]. J Med Chem，2021，64
signalling-biased mu opioid receptor agonist PZM21 in （18）：13394-13409.
non-human primates[J]. Br J Anaesth，2020，125（4）： [30] XU B，ZHANG M N，SHI X R，et al. The multifunctional
596-604. peptide DN-9 produced peripherally acting antinocicep‐
[19] MA M J，LI X，TONG K，et al. Discovery of biased tion in inflammatory and neuropathic pain via μ- and κ-
mu-opioid receptor agonists for the treatment of pain[J]. opioid receptors[J]. Br J Pharmacol，2020，177（1）：
ChemMedChem，2020，15（1）：155-161. 93-109.
[20] ZHUANG Y W，WANG Y，HE B Q，et al. Molecular reco- [31] WANG Y H，CHAI J R，XU X J，et al. Pharmacological
gnition of morphine and fentanyl by the human μ-opioid characterization of dezocine，a potent analgesic acting as a
receptor[J]. Cell，2022，185（23）：4361-4375.e19. κ partial agonist and μ partial agonist[J]. Sci Rep，2018，8
[21] DHILLON S. Tegileridine：first approval[J]. Drugs，2024， （1）：14087.
84（6）：717-720. [32] SETH R，KUPPALLI S S，NADAV D，et al. Recent ad‐
[22] KABIR A，MUTH A. Polypharmacology：the science of vances in peripheral opioid receptor therapeutics[J]. Curr
multi-targeting molecules[J]. Pharmacol Res，2022，176： Pain Headache Rep，2021，25（7）：46.
106055. [33] JIMÉNEZ-VARGAS N N，YU Y，JENSEN D D，et al.
[23] SMITH M T，KONG D H，KUO A，et al. Multitargeted Agonist that activates the µ-opioid receptor in acidified
opioid ligand discovery as a strategy to retain analgesia microenvironments inhibits colitis pain without side ef‐
and reduce opioid-related adverse effects[J]. J Med Chem， fects[J]. Gut，2022，71（4）：695-704.
2023，66（6）：3746-3784. [34] DEGRO C E，JIMÉNEZ-VARGAS N N，TSANG Q，et al.
[24] 陈泽权，肖国伟，敖健，等. 阿片受体激动-拮抗剂的镇痛 Evolving acidic microenvironments during colitis provide
作用及不良反应研究进展[J]. 中国药房，2023，34（18）： selective analgesic targets for a pH-sensitive opioid[J].
2299-2304. Pain，2023，164（11）：2501-2515.
CHEN Z Q，XIAO G W，AO J，et al. Research progress [35] FENG J，LEPETRE-MOUELHI S，GAUTIER A，et al. A
on analgesic effect and adverse drug reactions of opioid re‐ new painkiller nanomedicine to bypass the blood-brain
ceptor agonist-antagonists[J]. China Pharm，2023，34 barrier and the use of morphine[J]. Sci Adv，2019，5（2）：
（18）：2299-2304. eaau5148.
[25] MADA S，GERAK L R，SOYER A，et al. Behavioral ef‐ [36] LEBON B，ZEPPETELLA G，HIGGINSON I J. Effective‐
fects of benzylideneoxymorphone （BOM），a low efficacy ness of topical administration of opioids in palliative care：
µ opioid receptor agonist and a δ opioid receptor antago‐ a systematic review[J]. J Pain Symptom Manage，2009，37
nist[J]. Psychopharmacology，2020，237（12）：3591-3602. （5）：913-917.
[26] DING H P，KIGUCHI N，DOBBINS M，et al. Nociceptin （收稿日期：2023-12-29 修回日期：2024-08-14）
receptor-related agonists as safe and non-addictive analge‐ （编辑：胡晓霖）

· 2180 · China Pharmacy 2024 Vol. 35 No. 17 中国药房 2024年第35卷第17期